# Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant

> **NCT03862807** · PHASE3 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Amyloidosis, Familial
- Transthyretin Amyloidosis

## Interventions

- **DRUG:** Patisiran

## Key facts

- **NCT ID:** NCT03862807
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-27
- **Primary completion:** 2020-10-06
- **Final completion:** 2020-10-20
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03862807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03862807, "Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03862807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*